Degenerative Mitral Valve Disease Clinical Trial
Official title:
A Prospective, Multicenter, Objective Performance Criteria Study to Evaluate the Safety and Effectiveness of Dragonfly Transcatheter Mitral Valve Repair System for the Treatment of Degenerative Mitral Regurgitation (DMR) Subjects.
Verified date | June 2021 |
Source | Hangzhou Valgen Medtech Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of symptomatic moderate-to-severe(3+) or severe(4+) degenerative mitral regurgitation (DMR) in high surgical risk subjects.
Status | Enrolling by invitation |
Enrollment | 120 |
Est. completion date | May 31, 2027 |
Est. primary completion date | May 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 yrs. 2. Symptomatic moderate-to-severe (3+) or severe (4+) mitral valve regurgitation (DMR) confirmed by transthoracic echocardiography. 3. NYHA functional class II, III, IV. 4. Left ventricular ejection fraction (LVEF) = 20%. 5. Anatomically suitable for transcatheter mitral valve repair by edge-to-edge technique, and can be treated by the DragonflyTM device, as assessed by the site investigators and confirmed by the echo core laboratory and eligibility committee. 6. High surgical risk as defined by either Society for Thoracic Surgery Risk Calculator score for valve replacement = 8 points; or STS score for valve repair = 6 points; or other high surgical risks. e.g. presence of =2 moderate to severe frailty factors; or the presence of possible surgical obstacles; or the presence of =2 major organ dysfunctions that could not be improved after surgery; or other surgical high-risk factors as determined by the local heart team. 7. Transseptal catheterization and femoral vein access is determined to be feasible. 8. The subject or subject's legal representative has been informed of the nature of the trial, willing to accept the experimental tests, and has provided written informed consent. Exclusion Criteria: 1. Echocardiographic evidence of intra-cardiac mass, thrombus, or vegetation. 2. The presence of other severe heart valve disease requiring surgical intervention. 3. Prior mitral valve leaflet surgery or transcatheter mitral valve intervention. 4. Estimated pulmonary artery systolic pressure (PASP) > 70 mm Hg assessed by echocardiography. 5. History of acute myocardial infarction in the prior 4 weeks or untreated clinically significant coronary artery disease requiring revascularization. 6. Any percutaneous cardiac intervention within the 30 days, or any cardiac surgery within the 6 months prior to randomization; or if, in the judgment of the investigator, the subject's femoral vein is unable to accommodate a 25F catheter or has an ipsilateral deep venous thrombosis; or the anatomy is not accessible for transseptal puncture. 7. Subjects in whom transesophageal echocardiography (TEE) or general anesthesia is contraindicated. 8. End-stage heart failure (ACC/AHA stage D), or prior orthotopic heart transplantation, or on the waiting list for a heart transplantation. 9. Active endocarditis, or active rheumatic heart disease, or leaflets degenerated from either endocarditis or rheumatic disease. 10. Cerebrovascular accident within 30 days prior to randomization or symptomatic severe carotid stenosis (> 70% by ultrasound). 11. Evidence of acute peptic ulcer or gastrointestinal hemorrhage in the prior 3 months. 12. Hemorrhagic or coagulopathic disorders, contraindications to antithrombotic medication. 13. Modified Rankin Scale =4. 14. The subjects suffer from diseases which may lead difficulty in evaluating treatment (e.g., cancer, severe metabolic disease, psychosis, etc.); 15. Pregnant or breastfeeding women. 16. Hemodynamic instability defined as systolic pressure < 90 mmHg without afterload reduction, cardiogenic shock, or the need for inotropic support or an intra-aortic balloon pump. 17. Active infections requiring antibiotic therapy (in the case of temporary illness, antibiotics must be discontinued for at least 14 days before the subject can be enrolled). 18. Currently participating in an investigational drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. 19. In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study. |
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Hangzhou Valgen Medtech Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of major adverse events (MAEs) | MAE is defined as a combined clinical endpoint of death, stroke, myocardial infarction, renal failure, and nonelective cardiovascular surgery for device or procedure-related adverse events occurring after transseptal catheterization. | 30 days, 6 months, and 12 months | |
Other | All-cause mortality | Percentage of all-cause death includes cardiac death, non-cardiac death, and death from unknown causes. | 30 days, 6 months, and 12 months | |
Other | Cardiac mortality | Percentage of cardiac death | 30 days, 6 months, and 12 months | |
Primary | Treatment success | Percentage of patients freedom from: death, surgery for valve dysfunction, and MR > 2+ (moderate to severe (3+) or severe (4+) mitral regurgitation) . | 12 months | |
Secondary | Acute procedural success | Successful in Dragonfly implantation, and residual MR of 2+ or less at discharge. An echocardiography echocardiogram at 30 days can be accepted if the discharge image was not available or hard to interpret. A death before discharge or a re-operation of mitral valve prior to 30 days is defined as acute procedure failure. | Immediately after procedure, Discharge: 1 day after the patient's exit from the cardiac catheterization laboratory | |
Secondary | Acute device success | One or more Dragonfly devices are successfully delivered and released, edge-to-edge leaflet repair confirmed by echocardiogram, and successfully withdrawal of the delivery catheter. | Immediately after procedure | |
Secondary | Composite of function and re-operation measures | Number of patients freedom from postoperative surgery for mitral valve dysfunction. | 30 days, 6 months, and 12 months | |
Secondary | NYHA Class | Number of patients with New York Heart Association (NYHA) Function Class I or II. | 30 days, 6 months, and 12 months | |
Secondary | Quality of life improvement | Improvement in quality of life (QoL) at 12 months over baseline, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03290872 -
Mitral Annuloplasty Rings RCT
|
N/A | |
Completed |
NCT05774769 -
Commissural Closure to Treat Severe Mitral Regurgitation: Standing the Test of Time.
|
||
Completed |
NCT05836532 -
Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
|
||
Completed |
NCT05839782 -
Long Term Results in Redo Mitral Valve Surgery After Mitral Valve Repair
|
||
Recruiting |
NCT03706833 -
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
|
N/A | |
Recruiting |
NCT05655897 -
Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation
|
N/A | |
Enrolling by invitation |
NCT04067635 -
Primary Mitral Regurgitation Repair
|
||
Active, not recruiting |
NCT06021509 -
Clinical Study of NovoClasp for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation
|
N/A | |
Not yet recruiting |
NCT04679662 -
EXPLORE DMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Degenerative Mitral Regurgitation
|
N/A | |
Active, not recruiting |
NCT04281940 -
Chordal Repair for Transcatheter Mitral Valve Repair (TMVr)
|
N/A | |
Not yet recruiting |
NCT05417945 -
A Prospective, Multicenter Study to Evaluate the JensClip Transcatheter Valve Repair System
|
N/A | |
Recruiting |
NCT03433274 -
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
|
N/A | |
Active, not recruiting |
NCT03674593 -
Clinical and Fundamental Aspects of Prosthetics and Translocation of Mitral Valve Chordae
|
N/A | |
Recruiting |
NCT05595226 -
Effect of RT3D-TEE-guided Mitral Valve Repair on Outcomes in Patients With Degenerative Mitral Valve Disease
|
N/A | |
Terminated |
NCT04666480 -
Early Feasibility Study of the PLAR Implant and Delivery System to Treat Degenerative Mitral Regurgitation
|
N/A |